|
Cystathioninuria
|
0.940 |
Biomarker
|
phenotype |
BEFREE |
From genomic DNA, we sequenced CTH in four unrelated probands with cystathioninuria.
|
12574942 |
2003 |
|
Cystathioninuria
|
0.940 |
Biomarker
|
phenotype |
BEFREE |
We previously generated mice lacking cystathionine γ-lyase (Cth) as cystathioninuria models and found them to be with cystathioninemia/homocysteinemia.
|
31319489 |
2019 |
|
Cystathioninuria
|
0.940 |
GeneticVariation
|
phenotype |
BEFREE |
Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria.
|
20584029 |
2010 |
|
Cystathioninuria
|
0.940 |
GeneticVariation
|
phenotype |
BEFREE |
Each affected child was homozygous for the novel DGUOK p.D255Y mutation, but had no CTH mutation, indicating that the hepatocerebral form of MDS might be associated with secondary cystathioninuria.
|
15887277 |
2005 |
|
Gamma-cystathionase deficiency
|
0.940 |
Biomarker
|
disease |
BEFREE |
From genomic DNA, we sequenced CTH in four unrelated probands with cystathioninuria.
|
12574942 |
2003 |
|
Gamma-cystathionase deficiency
|
0.940 |
GeneticVariation
|
disease |
BEFREE |
Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria.
|
20584029 |
2010 |
|
Gamma-cystathionase deficiency
|
0.940 |
Biomarker
|
disease |
BEFREE |
We previously generated mice lacking cystathionine γ-lyase (Cth) as cystathioninuria models and found them to be with cystathioninemia/homocysteinemia.
|
31319489 |
2019 |
|
Gamma-cystathionase deficiency
|
0.940 |
GeneticVariation
|
disease |
BEFREE |
Each affected child was homozygous for the novel DGUOK p.D255Y mutation, but had no CTH mutation, indicating that the hepatocerebral form of MDS might be associated with secondary cystathioninuria.
|
15887277 |
2005 |
|
Fetal Growth Retardation
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
This low CGL reduced cysteine and taurine concentrations in IUGR pigs and led to an accumulation of hepatic cystathionine, with lower homocysteine concentrations.
|
22137257 |
2012 |
|
melanoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.
|
25205294 |
2015 |
|
Cystathioninemia
|
0.110 |
Biomarker
|
disease |
BEFREE |
We previously generated mice lacking cystathionine γ-lyase (Cth) as cystathioninuria models and found them to be with cystathioninemia/homocysteinemia.
|
31319489 |
2019 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
We previously reported that cystathionine γ-lyase knockout (CSE-KO) male mice develop atherosclerosis earlier than male wild-type (WT) mice.
|
27986657 |
2017 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cystathionine γ lyase (CSE) is the major source of hydrogen sulfide-derived species (H<sub>2</sub>S<sub>n</sub>) in endothelial cells and plays an important role in protecting against atherosclerosis.
|
31759247 |
2020 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, we aimed to evaluate the involvement of hydrogen sulfide (H <sub>2</sub> S)/cystathionine γ-lyase (CSE) in the pathogenesis of AS as well as their possible signaling pathways.
|
30246263 |
2019 |
|
Arteriosclerosis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of HDAC6 activity may improve endothelial function and prevent or reverse the development of atherosclerosis.<b>NEW & NOTEWORTHY</b> Oxidative injury to endothelial cells by oxidized LDL reduced cystathionine γ-lyase (CSEγ) expression and H<sub>2</sub>S production, leading to endothelial dysfunction, which was prevented by histone deacetylase 6 (HDAC6) inhibition.
|
28188215 |
2017 |
|
Atherosclerosis
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of HDAC6 activity may improve endothelial function and prevent or reverse the development of atherosclerosis.<b>NEW & NOTEWORTHY</b> Oxidative injury to endothelial cells by oxidized LDL reduced cystathionine γ-lyase (CSEγ) expression and H<sub>2</sub>S production, leading to endothelial dysfunction, which was prevented by histone deacetylase 6 (HDAC6) inhibition.
|
28188215 |
2017 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, we aimed to evaluate the involvement of hydrogen sulfide (H <sub>2</sub> S)/cystathionine γ-lyase (CSE) in the pathogenesis of AS as well as their possible signaling pathways.
|
30246263 |
2019 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
We previously reported that cystathionine γ-lyase knockout (CSE-KO) male mice develop atherosclerosis earlier than male wild-type (WT) mice.
|
27986657 |
2017 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cystathionine γ lyase (CSE) is the major source of hydrogen sulfide-derived species (H<sub>2</sub>S<sub>n</sub>) in endothelial cells and plays an important role in protecting against atherosclerosis.
|
31759247 |
2020 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
The cystathionine γ-lyase/hydrogen sulfide (CSE/H<sub>2</sub>S) pathway have been associated with several cardiovascular diseases, but the effect of TFR on the Rho-associated protein kinase (ROCK) and CSE/H<sub>2</sub>S signaling pathways remains unknown.
|
31611932 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We also performed SNP analysis of H<sub>2</sub>S synthesizing enzymes and found a significant increase in cystathionine gamma-lyase (CTH) 1364 G-T allele frequency in patients with CVD compared to controls.
|
29413960 |
2018 |
|
Cardiovascular Diseases
|
0.040 |
AlteredExpression
|
group |
BEFREE |
However, the molecular mechanisms that control CSEγ gene expression in the endothelium during cardiovascular diseases are unclear.
|
28188215 |
2017 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Mounting evidence demonstrated deficient cystathionine-γ-lyase (CSE)/H<sub>2</sub>S implicated the development of cardiovascular disease.
|
28669627 |
2017 |
|
Hypertensive disease
|
0.040 |
Biomarker
|
group |
BEFREE |
<i>Cth</i><sup>-/-</sup> females developed normally but showed mild hypertension (~10 mmHg systolic blood pressure elevation) in late pregnancy and mild proteinuria throughout development/pregnancy.
|
31319489 |
2019 |
|
Hypertensive disease
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Upregulation of cystathionine-γ-lyase/hydrogen sulfide pathway underlies the celecoxib counteraction of cyclosporine-induced hypertension and renal insult in rats.
|
30658157 |
2019 |